全文获取类型
收费全文 | 30167篇 |
免费 | 2408篇 |
国内免费 | 156篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 256篇 |
妇产科学 | 482篇 |
基础医学 | 2362篇 |
口腔科学 | 40篇 |
临床医学 | 3608篇 |
内科学 | 584篇 |
皮肤病学 | 45篇 |
神经病学 | 155篇 |
特种医学 | 2319篇 |
外科学 | 5539篇 |
综合类 | 3609篇 |
预防医学 | 1568篇 |
眼科学 | 20篇 |
药学 | 1843篇 |
10篇 | |
中国医学 | 393篇 |
肿瘤学 | 9886篇 |
出版年
2024年 | 19篇 |
2023年 | 309篇 |
2022年 | 858篇 |
2021年 | 1140篇 |
2020年 | 1094篇 |
2019年 | 849篇 |
2018年 | 1050篇 |
2017年 | 1017篇 |
2016年 | 1066篇 |
2015年 | 1138篇 |
2014年 | 2419篇 |
2013年 | 2142篇 |
2012年 | 2030篇 |
2011年 | 2173篇 |
2010年 | 1666篇 |
2009年 | 1860篇 |
2008年 | 1942篇 |
2007年 | 1805篇 |
2006年 | 1450篇 |
2005年 | 1037篇 |
2004年 | 864篇 |
2003年 | 664篇 |
2002年 | 567篇 |
2001年 | 507篇 |
2000年 | 454篇 |
1999年 | 370篇 |
1998年 | 331篇 |
1997年 | 313篇 |
1996年 | 198篇 |
1995年 | 227篇 |
1994年 | 208篇 |
1993年 | 133篇 |
1992年 | 109篇 |
1991年 | 93篇 |
1990年 | 67篇 |
1989年 | 85篇 |
1988年 | 55篇 |
1987年 | 53篇 |
1986年 | 34篇 |
1985年 | 72篇 |
1984年 | 42篇 |
1983年 | 20篇 |
1982年 | 45篇 |
1981年 | 47篇 |
1980年 | 42篇 |
1979年 | 27篇 |
1978年 | 16篇 |
1977年 | 9篇 |
1976年 | 5篇 |
1975年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
91.
目的 探讨乳腺癌新辅助化疗前后肿瘤组织病理信息的变化及对预后的影响。方法 对2014年1月—2016年5月就诊于辽宁省肿瘤医院乳腺外科并行规范乳腺癌新辅助化疗的177例患者回顾性分析,探讨乳腺癌新辅助化疗前后肿瘤组织病理信息的变化,并分析残余肿瘤组织病理信息对无病生存期(DFS)和总生存期(OS)的影响。结果 177例乳腺癌患者中位随访时间为37个月,37个月无病生存率和总生存率分别为84.0%和95.0%,4年无病生存率和总生存率分别为79.7%和81.1%。新辅助化疗后乳腺癌患者的DFS独立危险因素为原始T分期、原始N分期、存在脉管侵袭、新辅助化疗后Ki-67增加。OS的独立危险因素为原始T分期、原始N分期。而新辅助化疗前后ER状态的改变、PR状态的改变、HER-2状态的改变与患者预后无关(P>0.05)。结论 乳腺癌新辅助化疗前后分子生物学指标ER、PR、HER-2、Ki-67可以发生改变,但与乳腺癌患者预后无关。原始肿瘤T分期、原始肿瘤N分期、存在脉管侵袭和Ki-67增加是影响乳腺癌患者DFS的危险因素。原始肿瘤T分期、原始肿瘤N分期是影响乳腺癌患者OS的危险因素。 相似文献
92.
93.
94.
95.
96.
《Gaceta sanitaria / S.E.S.P.A.S》2021,35(3):243-249
ObjectiveTo evaluate the effect of receiving information about the benefits and harms of breast cancer screening in informed choice, according to educational level.MethodSecondary analysis of a randomized, controlled study, in four screening programs, in Catalonia and the Canary Islands (Spain). We analyzed 400 women who were going to be invited to participate for the first time. The intervention group received a decision aid that showed the benefits and harms of screening. The control group received a standard brochure that recommended participating in the screening program. Educational level was grouped into two categories, low and high. The primary outcome was informed choice defined as adequate knowledge and consistency between attitudes and intentions.ResultsThe intervention produced a greater increase in knowledge in women with a high educational level compared to those with a lower educational level. Among women who received the intervention, informed choice was almost three times higher in those with a high educational level (27% versus 11%). No differences were observed between educational levels in decisional conflict, confidence in the decision, anxiety and worry about breast cancer, in the intervention and control groups.ConclusionsA decision aid for breast cancer screening had much more impact on informed choice among women with a high educational level. In women with low educational level, the attitude towards screening improved and there was an increase in the intention to be screened. 相似文献
97.
G.N. Marta D. Ramiah O. Kaidar-Person A. Kirby C. Coles R. Jagsi T. Hijal G. Sancho Y. Zissiadis J.-P. Pignol A.Y. Ho S.H.-C. Cheng B.V. Offersen I. Meattini P. Poortmans 《Clinical oncology (Royal College of Radiologists (Great Britain))》2021,33(5):322-330
AimsModerately hypofractionated breast irradiation has been evaluated in several prospective studies, resulting in wide acceptance of shorter treatment protocols for postoperative breast irradiation. Reimbursement for radiation therapy varies between private and public systems and between countries, impacting variably financial considerations in the use of hypofractionation. The aim of this study was to evaluate the financial impact of moderately hypofractionated breast irradiation by reimbursement system in different countries.Materials and methodsThe study was designed by an international group of radiation oncologists. A web-questionnaire was distributed to representatives from each country. The participants were asked to involve the financial consultant at their institution.ResultsData from 13 countries from all populated continents were collected (Europe: Denmark, France, Italy, the Netherlands, Spain, UK; North America: Canada, USA; South America: Brazil; Africa: South Africa; Oceania: Australia; Asia: Israel, Taiwan). Clinicians and/or departments in most of the countries surveyed (77%) receive remuneration based on the number of fractions delivered to the patient. The financial loss per patient estimated resulting from applying moderately hypofractionated breast irradiation instead of conventional fractionation ranged from 5–10% to 30–40%, depending on the healthcare provider.ConclusionAlthough a generalised adoption of moderately hypofractionated breast irradiation would allow for a considerable reduction in social and economic burden, the financial loss for the healthcare providers induced by fee-for-service remuneration may be a factor in the slow uptake of these regimens. Therefore, fee-for-service reimbursement may not be preferable for radiation oncology. We propose that an alternative system of remuneration, such as bundled payments based on stage and diagnosis, may provide more value for all stakeholders. 相似文献
98.
Seung Ki Min Se Kyung Lee Jinsun Woo Sung Mi Jung Jai Min Ryu Jonghan Yu Jeong Eon Lee Seok Won Kim Byung Joo Chae Seok Jin Nam 《JOURNAL OF BREAST CANCER》2021,24(1):75
PurposeTumor size and lymph node metastasis are important factors that contribute to the progression of breast cancer. We aimed to analyze the relationship between tumor size and lymph node metastasis molecular subtype and examine the effects of nodal metastasis on overall survival (OS).MethodsWe retrospectively reviewed the data of 16,552 patients who underwent breast surgery in Samsung Medical Center between 2000 and 2015. Information on tumor size (largest diameter of the invasive component), number of positive lymph nodes, and molecular subtype were obtained. We constructed a linear regression model to evaluate the relationship between tumor size and lymph node metastasis. To determine the effect of nodal metastasis on OS, we performed a Cox proportional regression analysis with Np/T (number of metastatic lymph nodes [n]/tumor size [cm]).ResultsThis study included 12,007 patients with a median follow-up of 62 months. The linear regression coefficients were 1.043 for luminal A, 1.024 for luminal B, 0.656 for HER2, and 0.435 for triple-negative breast cancer (TNBC) subtypes. No significant difference was observed in the coefficients between the luminal A and B subtypes (p = 0.797), while all other coefficients showed significant difference. After adjusting for other risk factors, the hazard ratio (HR) of Np/T for each subtype was significant for OS: luminal A (HR, 1.134; 95% confidence interval [CI], 1.097–1.171; p < 0.001), luminal B (HR, 1.049; 95% CI, 1.013–1.086; p = 0.007), HER2 (HR, 1.069; 95% CI, 1.014–1.126; p = 0.013), and TNBC (HR, 1.038; 95% CI, 1.01–1.067; p = 0.008).ConclusionThe incidence of lymph node metastasis differed according to molecular subtype. Luminal types have higher incidence of nodal metastasis than HER2 and TNBC. The HR of Np/T was highest in luminal A subtypes and lowest in TNBC subtypes. 相似文献
99.
BackgroundThe use of endocrine therapy for early-stage breast cancer, particularly aromatase inhibitor therapy has been associated with an increased risk of osteoporosis and fracture in clinical trials. We sought to validate this observation in real-world practice.MethodsWe used health administrative data collected from post-menopausal women (aged ≥66 years) who were diagnosed with breast cancer and started on adjuvant endocrine therapy from 2005 to 2012. Patients were classified by use of either an aromatase inhibitor or tamoxifen and followed until 2017 for a new diagnosis of an osteoporotic fracture. A multivariable analysis using a Cox proportional hazards model was adjusting for age, medical co-morbidities, medication use and duration of endocrine therapy.ResultsWe identified 12,077 patients of whom 73% were treated with an aromatase inhibitor as compared to 27% with tamoxifen. Our multivariable analysis did not demonstrate any significant difference in the rate of osteoporotic fracture between patients treated with an aromatase inhibitor when compared with tamoxifen [Hazard ratio (HR) = 1.09; 95% confidence interval (CI) = 0.96–1.23, p-value = 0.18]. The 5-year rate of osteoporotic fracture for patients treated with either an aromatase inhibitor or tamoxifen was 7.5% and 6.9%, respectively. A completed sensitivity analysis did observe a decreased risk of fracture associated with tamoxifen usage over time.ConclusionWe could not detect a significant difference in the rate of osteoporotic fracture among patients treated with an aromatase inhibitor versus tamoxifen. Nonetheless, the risk with tamoxifen was numerically lower and significantly decreased when accounting for total duration of endocrine therapy. 相似文献
100.
Juana María Brenes Sánchez Amanda López Picado María Eugenia Olivares Crespo José Ángel García Sáenz Rosa María De La Plata Merlo María Herrera De La Muela 《Clinical breast cancer》2021,21(1):e128-e135
BackgroundFrom the first case of SARS-CoV-2 infection in Wuhan (China), the infection spread all around the world causing a pandemic of coronavirus disease-2019 (COVID-19). Spain has been one of the most severely affected countries, and Madrid has reported a high number of cases and deaths. We discuss our strategies for optimal breast cancer management during COVID-19 pandemic.Patients and MethodsThis was a retrospective observational study at Clínico San Carlos Hospital to analyze the management of patients with breast cancer during the pandemic outbreak and the surgical strategy after the pandemic outbreak. We created a practical and dynamic tool based on a “traffic light” system for prioritizing surgical time. Every patient was contacted by telephone with a preoperative COVID-19 protocol. After surgical procedures, patient satisfaction was assessed using the European Organisation for Research and Treatment of Cancer in-patient satisfaction with cancer care questionnaire (EORTC IN-PATSAT32).ResultsPatients with breast cancer actively treated with surgical procedures were put on a waiting list and received systemic therapy. Telemedicine was used to evaluate any side effects and to avoid unnecessary hospital visits. Surgery was only considered after the pandemic outbreak, and then, only those procedures designed to minimize surgical complications and, therefore, reduce hospital stay. We also measured patients’ satisfaction with medical and nursing scales that resulted in a “very good” evaluation tending to “excellent”.ConclusionIt is necessary to adapt management of oncology treatment and surgical strategy to optimize resources during the COVID-19 pandemic. Patients’ perception of care quality and the degree of patients’ satisfaction with health services has potential relevance in the absence of outcome data. 相似文献